ストックスクリーナーアプリを入手
2.44
2.52%
0.06
アフターアワーズ：
2.45
0.01
+0.41%
前日終値:
$2.38
開ける：
$2.4
24時間の取引高:
1.14M
Relative Volume:
0.60
時価総額：
$236.47M
収益：
$20.76M
当期純損益:
$-132.49M
株価収益率:
-0.9139
EPS:
-2.67
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
-1.21%
1か月 パフォーマンス:
-0.81%
6か月 パフォーマンス:
+79.41%
1年 パフォーマンス:
-39.15%
1日の値動き範囲:
$2.2901
$2.4586
1週間の範囲:
$2.2901
$2.6298
52週間の値動き範囲:
$1.085
$5.10
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.44 | 230.66M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-15 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
How C4 Therapeutics Inc. stock responds to policy changes2025 Support & Resistance & Growth Focused Investment Plans - newser.com
Using economic indicators to assess C4 Therapeutics Inc. potentialWall Street Watch & Accurate Entry/Exit Alerts - newser.com
C4 Therapeutics Inc. stock trend forecastJuly 2025 Selloffs & Detailed Earnings Play Strategies - newser.com
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Using data models to predict C4 Therapeutics Inc. stock movement2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
What data driven models say about C4 Therapeutics Inc.’s futureMarket Performance Summary & Fast Moving Stock Watchlists - newser.com
Why hedge funds are buying C4 Therapeutics Inc. stockJuly 2025 Patterns & Precise Swing Trade Entry Alerts - newser.com
Volatility clustering patterns for C4 Therapeutics Inc.Trade Entry Summary & Safe Capital Allocation Plans - newser.com
Live market analysis of C4 Therapeutics Inc.July 2025 Recap & Capital Efficient Trade Techniques - newser.com
Is C4 Therapeutics Inc. stock positioned for digital transformationJuly 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
Camp4 Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How C4 Therapeutics Inc. stock benefits from strong dollarJuly 2025 Retail & Real-Time Volume Analysis Alerts - Fundação Cultural do Pará
Will earnings trigger a reversal in C4 Therapeutics Inc.July 2025 Drop Watch & Weekly Watchlist for Consistent Profits - newser.com
Can trapped investors hope for a rebound in C4 Therapeutics Inc.2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics Raises Cash And Wins Wall Street’s Favor - Finimize
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
C4 Therapeutics Reports Q3 2025 Financial Results - TipRanks
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
C4 Therapeutics Inc (CCCC) Q3 2025 Earnings: Revenue Surpasses E - GuruFocus
C4 Therapeutics Q3 revenue beats estimates - MarketScreener
C4 Therapeutics, Inc. SEC 10-Q Report - TradingView
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Real time pattern detection on C4 Therapeutics Inc. stockQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Using data filters to optimize entry into C4 Therapeutics Inc.2025 Buyback Activity & Daily Profit Focused Screening - newser.com
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
C 4 Therapeutics Inc (CCCC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):